When Healing Becomes a Crime

R

Rick

Guest
Wasn't sure whether to put this under diet and health or in the pathocratic forum. Now we have the technical term for pathocrats in the medical field: Allopaths.

link

When Healing Becomes a Crime

by D. Saul Weiner

Harry Hoxsey claimed to cure cancer using herbal remedies, and thousands of patients swore that he healed them. His Texas clinic became the world’s largest privately owned cancer center with branches in seventeen states, and the value of its therapeutic treatments was upheld by two federal courts. Even his arch-nemesis, the AMA, admitted his treatment was effective against some forms of cancer. But the medical establishment refused an investigation, branding Hoxsey the worst cancer quack of the century and forcing his clinic to Tijuana, Mexico, where it continues to claim very high success rates.1

Those interested in healing, politics, economics, or cancer will find a great deal of interest in Kenny Ausubel’s telling of the Hoxsey story. Ausubel is a meticulous investigative journalist and filmmaker, did prodigious research into the subject matter, and carefully presents the story, including interviews with several Hoxsey critics in orthodox medicine.

Those familiar with the field of alternate medicine will recognize that Hoxsey’s persecution is not an isolated phenomenon; many practitioners who have been viewed as a threat to the dominant mode of practice have been attacked without justification. However, there are a number of elements of the Hoxsey story which make it a dramatic and fascinating one. For one, Hoxsey would not easily back down when the AMA began its smear campaign in the 1920’s. Hoxsey fought aggressively in the courts, made savvy use of the media to counter AMA propaganda, and challenged the establishment in medicine to perform a fair scientific study of his treatment. Ausubel presents great archival footage to bring these battles to light. Also vital to Hoxsey's case was the tremendous support of his patients and his ability to win over a variety of professionals who overcame their initial skepticism about his protocol. Finally,Hoxsey was also a successful oil man; in addition to his great determination and belief in his cause, he also had the financial wherewithal to carry on the good fight. In the end, though, the FDA put him out of business in 1960 based on alleged technical violations.

Ausubel does a nice job of placing the Hoxsey story in the context of a centuries-old battle between 2 schools of medicine, the allopathic and the empiric. Allopathic doctors use aggressive treatments which they consider to be scientific. In the 19th century, these were mainly bleeding, the use of toxic minerals, and surgery. The empiric tradition emphasizes stimulating the body’s own defenses and favors the use of plant remedies; it is also based more on observation and experience than theory. Though there was a rivalry between the 2 schools during the 19th century, and doctors would denigrate empiric healers as quacks, there was a balance of power. Patients had substantive choices in terms of what type of healer they patronized. In the early 20th century, the AMA joined forces with the major financiers of the day to develop a lucrative approach to the practice of medicine, based on advances in surgery, the discovery of radiation, and the development of synthetic drugs. It pushed through changes in educational and licensing standards which served to exclude the empiric healers. In the process, allopathic medicine largely drove out the competition and acquired a monopoly on medical practice. While this history may not come as a shock to libertarian viewers, it would likely be eye-opening to those who subscribe to the conventional views that entities such as licensing boards and public health departments are working in the patient’s best interest.

One patient in particular eloquently expresses the libertarian perspective when she states "I think that we should have freedom of information and then we should have freedom of choice, and that should be made available to the public, and then let them choose what they’re going to take … we’re all adults, mainly, and in charge of our own destiny and we should be allowed to go whatever route we think would be best for us."

Advocates of economic freedom often talk about the greater efficiency that comes with a free market, in terms of higher quality, more choice, and lower cost. While all of these contentions are valid, the listener may not be moved by such a clinical presentation. In a great film such as this, we see that when healing becomes a crime, we put our very lives at stake. We have seen the tragic consequences that result when the state treats vices as crimes. Here we have the even greater absurdity of the virtuous act of healing getting twisted into a criminal offense. This documentary vividly demonstrates the high price we pay when we limit health freedom.

Note

1. From the book When Healing Becomes a Crime, by Kenny Ausubel (2000). Most of this review relates to Ausubel’s documentary: Hoxsey: How Healing Becomes a Crime, which was released in 1987. The movie was released on DVD in 2005 and includes special features, including an interview with Ausubel describing the developments which have taken place subsequent to making the documentary.
There's also a very good documentary on this here

I've wondered, also, whether the Hoxsey formula contains Dichloroacetate (DCA) that was recently in the news as "cheap, safe drug kills most cancers".
 
Here is something from The Hoxsey Herbal Therapy.

Hoxsey therapy is compatible with other approaches to degenerative illness that are described as non-toxic, holistic, or metabolic. "We consider cancer a systemic disease," Harry Hoxsey wrote in his book You Don't Have to Die (New York: Milestone Books, 1956). "It occurs only in the presence of a profound physiological change in the constituents of body fluids and a consequent chemical imbalance in the organism." Mildred adds, "It's very simple: Hoxsey normalizes and balances the chemistry within the body. When you get everything normalized, the abnormal cells -- the tumor cells -- cease to grow. And very slowly the tumor is absorbed and excreted, and it's gone."

If there is a weakness in this theory it is its apparent vagueness. Modern medicine, after all, requires a therapeutic intervention to be exact and reproducible; Hoxsey herbs, in contrast, have not been explained in terms of established pharmacological criteria. In her defense, Mildred observes that, like Harry, she is a clinical practitioner and an empiricist -- not a research scientist. She is too preoccupied with helping patients -- working sometimes 12 or more hours a day -- to try to define precisely why the therapy appears to work.

New and Traditional Approaches

Still, the treatment offered today at Bio-Medical is by no means simplistic. There is advanced diagnostic equipment on the premises, the six resident Mexican M.D.s are well-qualified (and speak fluent English), patients' needs are considered individually, and there is an openness to employing other promising non-toxic measures as adjuncts. Mildred follows new developments in the field of diet and cancer, for example, and keeps up with the latest reports in conventional medical journals. In line with progressive research findings, megadoses of certain vitamins like C are prescribed. Psychology is seen as increasingly important. "Mental attitude goes a long way in healing," Mildred observes. "The patients who make it are often the ones who really want to live -- so they take their medicines, stay on the diet, and do the other things they're supposed to do."

Herbs provide the basis of the therapy. The oral medicines, intended to help eliminate toxins from the body and balance the metabolism, include potassium iodide, red clover, licorice, burdock, stillingia, barberis, poke root, cascara, prickly ash bark, and buckthorn bark. The powder and paste, applied to external cancers, contain escharotic agents -- commonly used to treat external malignancies before the advent of modern radiation and chemotherapy. In fact, most of the components of the Hoxsey medicines have been employed for centuries to treat cancer and other conditions.

Herbalism, of which Hoxsey therapy may be considered a branch, is the most ancient form of healing. Many modern conventional drugs are still derived from plants (for example, digitalis from foxglove). In October 1980 the Public Broadcasting System series Nova ("The Cancer Detectives of Lin Xian") reported that Chinese researchers have determined that a common local medicinal herb often inexplicably reverses the course of early forms of esophageal cancer.

In Canada, Essiac, an herb-based cancer therapy of Native American origin similar to Hoxsey, was in use with apparent success from 1924 through the late 1970s, when it was stopped by Canadian medical authorities. Yet herbalism continues to be denigrated in conventional medical circles. In 1968 the influential American Cancer Society (ACS) reported in its list of Unproven Methods of Cancer Management (which amounts to a blacklist of alternative approaches) that it "does not have evidence that treatment used at the Bio-Medical Center, including. . . the Hoxsey method. . . is of objective benefit in the treatment of cancer." [This analysis was updated slightly and published in 1990 as an article in CA, the ACS' journal for cancer clinicians.] Mildred observes, and the Cancer Society confirms, however, that no representative of the ACS has ever actually visited the Bio-Medical Center nor investigated the Hoxsey approach.

No One is Turned Away

Perhaps the most noteworthy feature of the Bio-Medical Center is the economics of its treatment. A one-time fee currently is asked of all patients; it guarantees a person therapy for the duration of his or her illness, including return visits for examinations and unlimited supplies of the Hoxsey medicines and nutritional supplements. (The only additional charges may be for outside lab work.)

Lack of money, however, does not prevent a person from receiving treatment. The subject is not even raised until after one has undergone diagnosis and received initial therapy. "Those who don't have the money," Mildred confirms, "say that, and they pay what they can monthly or later on. The door is always open here." A patient volunteered, "Mildred drives an old pickup truck, she lives in a house-trailer, and a lot of the doctors here walk to work. I'm very well pleased with the financial aspects." "The theory behind the one-shot fee," Mildred explains, "is that it helps encourage patients to keep coming back -- their only expense is travel -- so they can be followed up for five years or more. It prevents them from going off the program.

"Nobody ever gets a bill from here," she continues. "I never sent a bill in my life. Patients know what they owe. Patients actually pay more when they don't get a bill." Ultimately, Mildred Nelson is the central source of strength at the Bio-Medical Center. She is always available to her patients, and is never far from the two telephones which bring queries at all hours from people throughout North America and beyond. Extremely well-versed in cancer and its whole range of treatments, Mildred is an extraordinary clinician -- gentle, firm, cajoling, or reassuring as the individual patient's condition demands. An associate observes, "Mildred is the clinic director, the nurse, the psychologist, and, I guess you'd have to say, the mother figure. She fits into just about all of the different categories imaginable."
If you go to hoxsey.com site you wil find many different links to various articles about alternative cancer treatments and, also, a link to an article on the sixteen year old, Abraham Cherrix, who has been told by the courts that he cannot continue with his alternative cancer treatments, he is using the Hoxsey treatments, he has to use allopathic therapies such as chemotherapy and radiation. There is a thread on him here on the forum.
 
I have some interaction with a big pharma company. one day I was talking to one of manager about a novel which is written based on a ethics of pharma companies. At that time she recollected some thing happened in the company 15 yrs back. company announced internally about new compound which they found showed wonderful results on cancer and with in 2 months they simply stopped talking about , even to the enquiries . It is understandable that curing deseases is like suicide ( or killing gold egg laying chicken ) for pharma companies. they wont eliminate any desease and they won't allow any body to cure the deseases.
 
earth said:
It is understandable that curing deseases is like suicide ( or killing gold egg laying chicken ) for pharma companies. they wont eliminate any desease and they won't allow any body to cure the deseases.
And there we get to the crux of the matter. It's not just big pharma using drugs only to fight symptoms and not cure or prevent diseases/cancer it's the the entire system from governments on down. I saw an article today in which a nuclear scientist has stated that attacking Iran would backfire. Well, duh. The US has never invaded a country to bring "peace" or "disarm" them. Sowing chaos and fueling the military industrial complex is their prime motivation. The "cure" is almost always worse than the disease except for those who profit from it.

Here's another video which I haven't had a chance to view yet.

Nutricide - Criminalizing Natural Health, Vitamins, and Herbs

The Codex Alimentarius is a threat to the freedom of people to choose natural healing and alternative medicine and nutrition. Ratified by ... the World Health Organization, and going into Law in the United States in 2009, the threat to health freedom has never been greater.
This is the first part of a series of talks by Dr. Rima Laibow MD, available on DVD from the Natural Solutions Foundation, an non-profit organization dedicated to educating people about how to stop Codex Alimentarius from taking away our right to freely choose nutritional health.
Ostensibly Codex Alimentarius was created in 1963 by FAO and WHO to develop food standards. However, what it really does is lay down the groundwork for controlling diet and dietary supplements.

link (from June 2005)
Codex Alimentarius To Approve 'Vitamin Guidelines'
The Codex Alimentarius Commission (CAC) will be meeting here in Rome for a week-long conclave from 4 to 9 July, and one of the agenda points is the final approval of new world-wide vitamin guidelines that are expected to restrict availability of nutrient-containing supplements to consumers the world over. The text of the guidelines was finalized last November in Germany, by the Codex Committee on Nutrition and Foods for Special Dietary Uses. I will be reporting from the CAC meeting, attending as part of a delegation of the National Health Federation, one of the very few voices that argue the side of consumer freedom of choice inside the meetings, albeit without a vote.

These types of international regulation are elaborated without public input and even without the consent of national parliaments of the participating countries.

Each country entrusts its vote, which will eventually determine national laws as well, to one person, the head of the national Codex delegation. And Codex delegations are typically headed by relatively low level administrative employees of national health ministries. So we are having what amounts to international laws being developed over the heads of and without input from national legislative authorities, let alone the public that will face the consequences. Democratic procedure has been officially abolished in the name of globalizing the economy and "removing barriers to trade".

As reported in Food Navigator: New Codex guidelines on vitamins, minerals no longer guaranteed 20/06/2005- "A handful of countries are threatening the adoption next month of new world standards on how to set maximum levels of vitamins and minerals, reports Dominique Patton."
My comment: It appears that the supplement industry associations, especially IADSA, see the Codex process as a game with only two alternative outcomes: Either RDA dosages for supplements or safety-based dosages. Of course they prefer the safety base. No consideration seems to have been given to the fact that safety of vitamins and minerals, if assessed by standards that have been developed for toxic substances, is going to be little better than RDA dosages. Perhaps the German "safety evaluation" of vitamins and minerals should be a grim reminder of what can happen if safety is over-zealously protected...

Investigative journalist Peter Byrne introduces his article The Fate of Vitamins with the following words:

A low-profile organization created by the United Nations is about to ban global trade of many essential nutrients - and there may be nothing you can do to stop it.

- - -

Peter Byrne, according to his own site, has an uncanny ability to mine reportable nuggets of graft and corruption out of mountains of government and corporate records — not to mention human sources. He knows how to get inside the soul of self-serving systems — be they created by left-wingers, neocons, or non-ideologically-inspired criminals — and find the facts.

At first I was a bit skeptical about that characterization, but after reading the article, I tend to agree.

Byrne takes us behind the smoke-screens into a world of corporate globalization. International agencies which closely co-operate with big pharma and big food are well on the way to carving up a potentially lucrative health and foods market and turning it over to its "rightful owners", the big global players. While not catching all of the technical details of this complex matter, the insights and the "big picture" he paints are worth reading even for those who think they have a pretty good understanding of what is going on. Here is his article:

- - -


The Fate of Vitamins

A low-profile organization created by the United Nations is about to ban global trade of many essential nutrients—and there may be nothing you can do to stop it

By Peter Byrne

If you use vitamin and mineral supplements for health, you might want to fly over to Rome, Italy and crash the July 4-9 meeting of the Codex Alimentarius Commission, a little-known international body that wields immense power over the global food market. Should the Codex Commission approve the Draft Guidelines for Vitamin and Mineral Supplements on its agenda, 300 of the 420 basic vitamin and mineral products commonly used by European consumers will be banned from manufacture and trade inside the European Community.

The ban will seriously impact the export business of U.S.-based supplement companies and could eventually result in similar product restrictions being implemented here. The Codex story has received almost no attention in the corporate press and media; although badly garbled versions of the tale zing about in cyberspace, confusing many readers with conspiracy-laden mixtures of fact and fantasy. Which is not to blame the authors of these emails, since the Codex Alimentarius (Latin for "food code") Commission is so pathologically bureaucratic that its real intentions, and the probable consequences of its actions, are difficult to discern when wading through thousands of pages of jargon in its public reports. For example, it is not true that over-the-counter vitamins and minerals will be banned in the United States after August 2005...

Read the rest of the article here
I don't know about other people, but starting this winter I started supplementing my diet with about 5000 IUs of Vitamin D daily to offset what I don't get because of lack of sun exposure and I haven't gotten sick once this winter. I also supplement my diet with Vitamin B complex as well as Zinc and Manganese and I feel a whole lot better, sleep better and exercise better these days.

Here's the rest of the article.

There are so many self-interested players in the "L'affair Codex," that it is nearly impossible to get a straight answer about what it all means from any single participant. It is possible to piece together the basic story from public records, and by listening to what the various interest groups have to say (with several tons of heavily iodized salt). The bottom line of the story is that the emerging Codex regulations on vitamins and mineral supplements have almost nothing to do with promoting human health, and everything to do with facilitating the profits of multinational food and chemical corporations.
The Five Major Codex Players
From the point of view of the American health consumer, there are five major players: the Codex Commission, the European Parliament and the Council of the European Union, the United Nations, the World Trade Organization, and the U.S. Food and Drug Administration/U.S. Department of Agriculture. All of these institutions are involved in formulating rules and regulations to govern the production and distribution of food supplements. It is easy to conflate their separate, but related, institutional efforts. The fate of food supplements is not dependent upon any one of these institutions, but upon how they interact as a whole. The five organizations are working syncretically to transform the supplements market, not in favor of the consumer, but in favor of certain multinational corporations that stand to benefit from the resulting restriction of trade under the guise of promoting "free trade."
The History of Codex and Their Guidelines
Codex was created in 1962 by the Food and Agriculture Organization of the United Nations (FAO) and the U.N. World Health Organization (WHO) to "harmonize" world food trade. The several hundred regular "participants" at Codex meetings are drawn from the ranks of government regulatory agencies; food, chemical, and pharmaceutical corporations; industry trade groups; and non-profit "watchdogs" with various political agendas. To date, Codex has established 250 sets of rules regarding the manufacture and distribution of a variety of foods, from sardines to peanuts to pineapples, and including food additives and infant formula. (It is illuminating to learn that Codex has approved the use of cyclamates and saccharine—artificial sweeteners long banned in the U.S. as health risks—as well as Monsanto's aspartame.) After more than a decade of wrangling over political aims and technical details—far removed from the public eye—the commission will likely approve the Draft Guidelines for Vitamin and Mineral Supplements in July.

The Codex guidelines begin: "Most people who have access to a balanced diet can usually obtain all the nutrients they require from their normal diet." Vitamin and mineral food supplements are defined as concentrated forms of nutrients whose purpose is to supplement the normal diet when the vitamin and mineral intake from food is insufficient. From the point of view of universal healthcare, deciding exactly which nutrients, and how much of each, constitute a "normal" or a "balanced" diet is a large variable when attempting to prescribe a single standard across hundreds of dietary cultures.

But Codex is not about health. The guidelines define the minimum level of supplement use as 15 percent of the recommended daily allowance (RDA) suggested by the manufacturer. Maximum levels of use, or upper safe levels, are not to be calculated by reference to RDAs, but, and this is important, by "scientific risk assessment" based on generally accepted scientific data, taking into consideration, as appropriate, the varying degrees of sensitivity of different consumer groups and the daily intake of vitamins and minerals from other dietary sources.

The key phrase here is "scientific risk assessment." This investigatory technique is, according to many experts, more properly reserved for testing safe usage levels for chemicals and substances known to be inherently toxic or poisonous, not for evaluating nutrients that are known to be generally safe as ordinarily ingested. This emphasis in the guidelines, according to expert critics, closes the door on the possibility of setting upper safe limits based upon the benefits of using a particular nutrient. And by setting upper limits based upon the sensitivity of the most sensitive group—say, pregnant women who probably should not use a lot of Vitamin A—the legitimate needs of the rest of the population for healthy doses of Vitamin A are ignored; indeed, the masses may be forbidden to use more Vitamin A than pregnant women, except, perhaps, by a doctor's prescription. The "safe" upper limit paradigm is further driven downwards by the admonition that it be reduced in accord with the amount of, say, Vitamin A obtained from a normal diet. Under Codex, labels will advise the consumer not to exceed the maximum daily amount; and that the product "should be stored out of the reach of young children," (replacing a sentence in an earlier draft that required containers to be child-proof).

The Codex Commission, which is composed of voting representatives of most of the world's nations, has not yet set the exact maximum doses for vitamins and mineral supplements, but it is looking to the European Union Parliament, and other arms of the FAO/WHO for "scientific risk assessment" guidance in that regard. And that is basically all that the Codex guidelines say at this time.
Corporate Participants
It is instructive at this point to take a look at the American participants at the Codex Commission, i.e. public and private sector agencies, corporations, and organizations that actively participate in the commission's deliberations and wield considerable influence upon issues in which they are acknowledged to be "expert." Staff from the Dept. of Agriculture and the Food and Drug Administration represent the official position of the United States at Codex meetings. They are deeply involved in setting global standards, as are the staffs of food and drug regulatory agencies in most industrialized countries. (Codex funds "scholarships" for representatives from third world countries, many of which lack any regulatory bodies, but are still subject to WTO agreements and are affected by Codex regulations.)

From the corporate sector, official Codex participants include Amway Corp., Wyeth Pharmaceutical Co., DSM Nutritional Products, Mead Johnson Nutritionals, Bristol Myers Squibb Co., Nestle USA, Herbalife International, and a trade group called the Council for Responsible Nutrition (CRN). The latter's Web site features a "Myth vs. Facts" on Codex, which, to be blunt, is a self-serving spin that underplays the negative ramifications of the guidelines on mom & pop supplement businesses. CRN's membership includes Archer Daniels Midland Co., Cargill Health & Food Technologies, Bayer Corp., Wyeth Consumer Health, Weider Nutrition International Inc., Shaklee Corp., Nutraceutical Corp., Herbalife International of America, Kemin Foods, General Nutrition Centers, Inc., Cadbury Adams USA LLC, DSM Nutritional Products, Eastman Chemical Company, Mingtai Chemical LLC, and Monsanto Life Sciences Company. (A number of these corporations have several voices at the meetings, since representatives of corporate subsidiaries sit alongside participants from their parent companies. And corporate-funded lobby groups have separate voices.)

CRN had this to say about the Draft Guidelines—which it helped to write and of which it approves: "We in the industry have long maintained that maximum levels set by Codex or governments for contents of vitamins and minerals in supplements should be based solely and completely on safety, not on nutritional policy in general or the RDA in particular." It is instructive that the chemical formulations for naturally-occurring vitamins and minerals are not patentable, unlike pharmaceutical formulas. And the supplement market is huge—$16 billion a year in the U.S. alone. It easy to presume that pharmaceutical, chemical and agricultural concerns are working to grab market share through the back door: Codex.
Public Interest Groups
On the other side of the corporate interest equation, in theory, is the Washington D.C.-based Center for Science in the Public Interest, which along with sister non-profits from Japan and the United Kingdom has official status in the Codex proceedings. CSPI is funded by social engineering projects such as the Rockefeller Family Fund, John Merck Fund, and the Robert Wood Johnson Foundation. A spin-off from Ralph Nader's public interest organization, CSPI claims that Vitamin A, Vitamin D, and Vitamin B6 cause a host of horrible diseases. The non-profit, which is a quote mill for The New York Times reporters, pooh-poohs the common understanding that a variety of foods and supplements are healthy, such as soy, Vitamin C, antioxidants, and dietary fiber. To back-up its ultra-precaution, CSPI refers to media-ballyhooed studies of antioxidants and Vitamins A & E which purport to show that these substances are bad for health. (Experts at Harvard Medical School and Tufts University say that these studies are deeply flawed, largely because they were focused upon particular at-risk sub groups, and did not take the needs of general populations into account.)

CSPI's stance supporting restrictive standards for vitamin and minerals undercuts the usefulness of an otherwise fine environmentalist tool, the Precautionary Principle, by taking the position that since a vitamin could cause harm to relatively small groups of people if improperly used, it is permissible to ban it universally, regardless of its obvious and well-documented benefits for millions of people.

Further complicating the mix of opinion massaging the medium is the Hoover Institution, which has taken the position that Codex regulations hurt "free trade," (a loosely defined, if politically useful concept that is most often employed to justify the expansionist agendas of monopoly corporations). And the Center for Consumer Freedom, a restaurant trade association set up to counter "food police lies" about the dangers of tobacco, olestra, trans fats, and obesity, frames Codex as the "global food cop." Neither of these two organizations participate in Codex.
Institute of Medicine
And then there is the Institute of Medicine (IOM), a quasi governmental body based in Washington D.C. that performs scientific studies on spec from government and private companies. It is under U.S. government contract to develop standards for vitamins and minerals that reflect the standards being considered by Codex. From the point of view of the scientific establishment, IOM is no lightweight; it is very influential at the FDA, and inside the Codex/WTO complex.

A series of IMO studies over the past half-decade assert that high-fat diets lead to obesity and heart disease; that omega-3 fatty acids and linoleic acid are good for health; and that there is no safe level of consumption of trans fatty acids. (Codex regulations, on the other hand, allow for trans fats in food, and consider meat to be a source of dietary fiber!) A 2000 IOM report found that Vitamins C and E and the mineral selenium are health-positive, but that ceilings should be set on their usage. IOM believes that antioxidants can be beneficial. It suggests daily intakes of 75 milligrams of Vitamin C (upper level 2,000 milligrams); 22 IU of natural Vitamin E from food (upper level 1,500 IU of a synthetic variety); 55 micrograms of selenium, (upper level 400 micrograms). Beta Carotene supplementation, IOM says, should only be used to prevent Vitamin A deficiency. Pregnant women should take B vitamins, such as folate and choline to prevent neural tube defects. IOM posits that most Americans get sufficient Vitamin B12 in their food, except for people over 50 who should use supplements. IOM says there is promising evidence that B vitamins play a role in reducing cardiovascular disease, cancer, and psychiatric disorders. The Institute recommends upper levels of B6 at 100 milligrams per day; folic acid at 1,000 micrograms; and being wary of the rest of the B vitamins.

On the one hand, IOM has a higher regard for the health benefits of supplements than does Codex officialdom, which is focused upon risk. On the other hand, IOM is tending in the opposite direction of many knowledgeable health practitioners who typically recommend larger doses. For example, the medical doctors and nutritionists staffing Santa Rosa, California-based Farmacopia suggest, based on numerous studies and years of practice, a daily Vitamin C intake of 500-1,000 milligrams; Vitamin E intake of 400-800 IU; Vitamin A intake of 2,500-5,000 IU; Beta Carotene at 15 milligrams; and regular doses of the B vitamins, depending on need. Farmacopia's well-researched protocols spell out possible dangers from overdosing, such as nausea, diarrhea, and fingernail loss. However, they do not throw out entire nutrient groups, or suggest upper limit doses for whole populations based upon possible dangers to the most at-risk groups.

In reality, IOM's protocols are closer to Farmacopia's than to the more restrictive protocols supported by the ultra-precautionary forces at the Codex Commission. And this is, in part, because the IOM studies were funded by many of the same multinational corporations that are monitoring the Codex deliberations to make sure that government and non-profit bureaucrats do not go too far and end up liquidating the marketability of their supplement products. The IOM studies referred to above were funded not just by the U.S. Dept. Health and Human Services, but also by a variety of companies with varying degrees of interest in influencing Codex to set dose limits favorable to their respective business plans. These include Daiichi Fine Chemicals Inc., Kemin Foods Inc., M&M/Mars, Mead Johnson Nutrition Group, Nabisco Foods Group, Roche Vitamins Inc., U.S. Borax, and Weider Nutrition Group. The FDA, as we shall see, is now moving in the opposite direction of the less-restrictive IOM recommendations. It funded a new IOM study, the results of which reflect that sea-change in supplement policy.

Codex is nothing if not complicated. Its deliberations are fraught with competition and collusion by profit-driven companies and the non-profits that they fund to promote particular ideologies to justify particular business aims. Everybody at Codex is focused on grabbing the brass ring: as much market control as they can pinch off for themselves and their allies by tailoring the standards to fit their marketing needs. At stake in all the studies, discussions, political games, legal maneuvers, and media manipulation is nothing less than the determination of which vitamins and minerals end up on the "positive list," i.e. an exclusive list of approved dietary substances that spells life and death for any number of global product lines.
The Positive List
On April 5, 2005, the Alliance for Natural Health, an association of health food manufacturers and distributors in the United Kingdom announced a victory before the European Court of Justice in Luxembourg in the form of an opinion by Advocate General Geelhoed. The opinion will probably be adopted by the full court in June. The Alliance's victory, however, is likely to prove minor and temporary.

Here is the gist of the case. As of August 2005, dietary supplements in the European Union will be regulated by the Food Supplement Directive approved by the European Parliament and the Council of the European Union in June 2002. The directive calls for regulating vitamins and minerals by establishing a "positive list," which, in its current incarnation, includes 13 vitamin forms and 15 mineral forms. Nutrients not on the list will be banned from being sold in the EU. The approved substances are broken down by chemical composition, favoring synthetic compounds of natural forms, according to the Alliance for Natural Health. Substances not on the list include several forms of Vitamin C, natural forms of folic acid, certain antioxidants, and a range of minerals including boron, vanadium, silicon, mixed tocopherols, tocotrienols, sulphur, chelated/plant derived forms and natural forms of Vitamin E and selenium. Based on the positive list, the EU directive will effectively ban 300 of the 420 forms of vitamins and minerals present in 5,000 products currently on the UK market.

In response to the Alliance's lawsuit, the judge recommended invalidating the EU directive, but he upheld the concept of using a positive list to shape international markets, and he urged EU officials to correct what amounts to technical glitches in the wording of the directive, so that the positive list can be effectuated this summer.
Will the Existence of the Positive List Affect the American Market?
Undoubtedly, and here is how. First, in and of itself, the positive list will prohibit the importation of excluded substances and products into European Community markets. Second, the list is sure to be incorporated into the Codex guidelines for vitamins and minerals. That is because Codex is mandated to look to "accepted international standards" to determine which substances are allowed and not allowed and at what doses. It is widely accepted by informed observers that Codex will adopt the EU directive's positive list as its own standard, since there is no other internationally accepted standard.

In order for a nutrient substance to be added to the positive list, a comprehensive risk-assessment study must be performed, with favorable results submitted to the Office of the EU Communities by July 12, 2005. Even then, it can only remain on the positive list until 2009. These expensive scientific studies can only be undertaken by governments or corporations with deep pockets. In sum, the EU directive will likely destroy any European health supplement business which produces or sells commonly accepted vitamin and mineral products.

As for upper limit doses, the Codex Commission is looking to adopt the specifications of a study conducted by the FAO/WHO and various parties, including the Alliance for Natural Health. The study will set upper limit supplement dosage levels in the near future; and those standards, which will be based upon risk-assessment values, not health benefits, will be incorporated into the Codex Alimentarius regulations.

What does this mean for American consumers? Last year, the IOM, under contract with the FDA, issued a report called the Proposed Framework for Evaluation of Dietary Supplements. The report shifts IOM's previous focus upon health benefits to focus on scientific risk assessment. As in the Codex Guidelines, and the EU directive, IOM's report calls for safety issues to be considered as if there are no health benefits attached to the use of a vitamin or mineral. Furthermore, it recommends a method of setting maximum doses that may end up separating out ordinary usage (at relatively low levels) from prescriptive use (i.e., only medical professionals will be authorized to prescribe supplements above certain dosages in the course of medical interventions). And, as does Codex, the IOM report recommends putting the burden of supplying safety data upon industry—a strategy that has been proven not to work—see Merck's murderous mendacity about Vioxx.
The Argument for Codex
The FDA and several large US manufacturers, like DSM Nutritional Products, and Herbalife International, argue that the EU positive list directive and its doppelganger, the Codex guidelines, will not affect the ability of American consumers to use high doses of any supplement they wish to consume because the Codex guidelines and the EU directive are more restrictive than the Dietary Supplement Health and Education Act of 1994 (DSHEA); and the FDA is not adopting the positive list and its presumed low dosage standards, per se. In other words, American consumers will still be able to import European supplements because those products will be lower dosed than the current unlimited dosage levels allowed in the U.S. However, American supplement manufacturers and distributors will be locked out of the European regional markets, and the local markets of any country that adopts the Codex standards in order to benefit from trade with Europe.

Let us not forget that the same American corporations that sit on the Codex Commission as participants also wield tremendous power within the FDA and Congress. Above all, these corporations want access to—and exclusive control of—existing and emerging markets. For DSM Nutrition, for example, the Codex restrictions bring multiple benefits. They kill off small competitors, for all the reasons listed above, and also facilitate the development of two-tiered supplement products, a low dose vitamin for over the counter purchase, and a high dose, more expensive item for prescriptive use. Supplement users stuck in a Codex-controlled market will no longer be able to legally supply themselves with nutrients and doses of their own choosing; rather, they will be captive to the monopolies.

In March, the FDA observed that, "The absence of science-based Codex guidelines [in America] could adversely affect the ability of U.S. manufacturers to compete in the marketplace." This is true because the trade ministries of countries that adopt the Codex standards will repel non-Codexed products. But what the FDA did not say is that European supplement companies will no longer be able to compete in the U.S. market, because their products will be inferior to American products by fiat. And that phenomenon, under the WTO treaties that prohibit a government from "artificially" restricting "free trade," could hypothetically be construed to mean that our relatively loose FDA regulations "unfairly" restrict the ability of European producers to export to the American market, potentially forcing, under the WTO treaties, Congress to adopt Codex standards to facilitate "free trade." Whether or not it falls out like that, it is clear the FDA is moving under its own steam toward cloning the emerging Codex standards, which it helped to develop as a leading participant in commission deliberations.
A Brief Summary
To sum up so far: the Codex Commission is mostly composed of corporate officials from the agribusiness, pharmaceutical, and chemical industries, and government officials that "regulate" those industries (often after or before working for those same privately-owned industries). Codex is poised to adopt a "scientific risk assessment standard" for evaluating vitamins and mineral food supplements. Due to the use of that method of analysis, as opposed to a "risk-benefit" analysis method, the Codex standard will likely incorporate the positive list of the EU directive. It may adopt upper dosage limits that are lower than RDA doses currently available in ordinary supplements. (Higher doses may later be regulated as prescription-only drugs.) In Europe, hundreds of relatively small supplement manufacturers and distributors fear that the new Codex restrictions will annihilate their businesses—leaving the field open to corporations that can afford the expense of having proprietary, synthetic supplements added to the positive list through 2009, long enough, perhaps, to ensure domination of a drastically reshaped market.

The Codex restrictions ensure that the quantity and quality of supplements that can be imported by the European market from America will diminish. But in the U.S. there is a government-corporate propaganda campaign dedicated to assuring American consumers and small supplement producers that they are in no danger of ending up like their European counterparts. Large companies such as Herbalife International say that anyone who suggests that Americans will lose access to supplements is plying "misinformation." The company goes so far as to tell its international network of distributors that corporate HQ represents them at Codex meetings, and they will be told when, if ever, to open their mouths. In July 2003, the Consumers Union hailed the scientific risk assessment standards of Codex. American Herbal Products is slightly more perspicacious. This trade association recognizes that the WTO can, at least in theory, push the Codex standards upon Americans.
Why Is There Confusion About Codex?
One of the reasons that U.S. trade associations and consumers are confused about Codex—and why pro-Codex lobbyists, such as the FDA and the CRN, can dismiss the legitimate concerns of consumers as conspiracy theories—is because, due to the complexity of the bureaucracy at work, people have conflated the Codex Guidelines (which has no positive list, nor an upper dose limit, yet) and the EU directive (which does have a positive list, but no upper dose limit, yet). Reading the FDA's or CRN member's barrage of disclaimers about the negative impact of Codex upon the U.S., one is struck by the shared mantra that compliance with Codex is "voluntary," when, in truth, non-compliance may result in trade sanctions or expulsion from the WTO. Another popular phrase that pops up in the campaign, "science-based risk assessment," sounds nice until you realize it is a technique more aptly applied to arsenic or cyclamates, than to Vitamin E, which has known benefits, (as well as some risk if used improperly).

The fact that too much of a good thing can cause harm has been blown out of proportion by Codex proponents. For instance, a study of the effects of Vitamin E upon smokers and cancer victims has been widely publicized as "proving" that the vitamin has no positive effect on health (and may result in death); whereas dozens of unpublicized, scientifically-superior studies show that Vitamin E has many benefits (and that the negative study was deeply flawed). Or take the case of the amino acid, L-tryptophane, demonized a few years back after a genetically-engineered batch manufactured in Japan was fatally contaminated. Instead of questioning the efficacy of genetic engineering as a manufacturing strategy, or the wisdom of replacing natural substances with synthetic, proprietary goop, the pharmaceutical-regulatory establishment attacked L-tryptophane in all of its forms, many of which are beneficial. Underlying all the public relations blather, and reams of subjectivized, financially compromised studies, is the fact that world trade in food supplements is being restricted and transformed for the worse under the guise of eliminating trade restrictions and promoting health.
Enter the WTO
Contrary to rumor, Vitamin C will not be banned in the U.S. in August. But some forms of it will be banned in the EU; and a similar ban could eventually appear in the U.S., although that event is not inevitable. On the other hand, it will be much more difficult for ordinary consumers to stop this eventuality than it was for them to affect DSHEA, which was transformed by consumer pressure from a restrictive measure into its opposite. In fact, the very existence of DSHEA is used by Codex proponents as "proof" that the U.S. is protected against Codex, because DSHEA is "less restrictive" than Codex and the EU directive. That is hollow reassurance.

DSHEA is a malleable act of Congress, subject to constituent pressure. The implementing force of Codex—the WTO—is based upon an international treaty to which the United States is a party. And the WTO does not care a fig for people's health concerns. It is designed to manipulate the formation and deformation of trade barriers in favor of the strongest monopolists.

Here is how it works. The WTO derives its power to regulate international trade through treaties. In the age of the political, cultural, and economic dominance of multinational corporations, it acts as a kind of clearing house, or court of last resort, to settle trade disputes short of war. In theory, the WTO is concerned that no country favor its own exports by placing "unfair" restrictions upon competing imports.

Run by and for the interests of large industrial and financial enterprises, the WTO views "harmonization" of food standards as promoting "free trade." Unfortunately, free trade as conceptualized and actualized by the dominant WTO members (United States, European Union, Japan) is not about leveling the playing field so that small producers or underdeveloped countries can compete with the big guys. It is about ensuring that the most powerful corporations can continue to grow, eating up the small fish and expanding into new markets in both industrialized and industrializing economies. It is about maximizing the extraction of profit for stock-holders, as opposed to maximizing the health or economic well-being of a population.

To that end, WTO members have agreed to abide by the Agreement on Sanitary and Phytosanitary Measures (SPS), and the Technical Barriers to Trade Agreement (TBT), which mandate that no country will impose unfair barriers to trade, and that they will work to harmonize regulations that affect trade by abiding by international standards, or face trade sanctions. In theory, this could mean that the United States, by allowing the internal sale of substances and supplement doses that are disallowed in Europe is, in effect, imposing a barrier to the "free trade" of EU supplements, since consumers are less likely to buy products that are diluted by Codex restrictions. And the FDA, which is clearly controlled by the pharmaceutical and agribusiness sector, is in the process of harmonizing the internal market, partly through the scientific auspices of the IOM, in a way that parallels the EU Community and Codex processes. From the perspective of the WTO, it is not harmonious to have one relatively unrestricted supplement market, governed by DSHEA, surrounded by a more restricted world market bound under Codex. Since it is, when all is said and done, in the interests of the WTO movers and shakers to carve up the food supplement market amongst themselves, while excluding small producers, it is likely that the movement to mirror the Codex restrictions in America will continue. And should that fail, the SPS and TBT treaties ensure that legal actions can be mounted by European governments at the WTO level to compel the U.S. to toe the Codex line, or pay the price of non-compliance.

(It is important to note that food and food supplements are only one area of commerce that the WTO and the United Nations are attempting to harmonize. Ultimately, world trade will increasingly fall under the spell of monopoly as commodities become uniformly regulated in conformance with the Neoliberal economic doctrine [the so-called "Washington Consensus"] that currently prevails in the White House, at the United Nations Security Council, and inside the WTO.)
The Irony of the Situation
The ultimate irony, some might say horror, of the situation is highlighted by looking at a joint report by the FAO/WHO issued in 2003, Diet, Nutrition and the Prevention of Chronic Disease. This impeccably researched, enormously valuable study—performed by other arms of the same organizations that administer Codex—finds that the health of Third World populations is being destroyed by importing the First World diet, which is heavy in saturated fats, trans fats, unrefined carbohydrates and sugar, meat, dairy, while lacking in vegetables, fruits, and dietary fiber. This unhealthy diet, says the FAO/WHO, is spreading around the globe "like an infectious disease."

Without mentioning Codex, the report implicitly damns the commission's methods and its guidelines for vitamins and minerals. For example, the report notes that "[Food] guidelines should try to ensure that the overall benefit of recommendations to the majority of the population substantially outweigh any potential adverse effects on selected subgroups." In other words, upper dosage limits for supplements should be set to benefit the population as a whole, not calculated, say, on the potential for excessive intake of Vitamin A to harm a fetus.

"Population nutrient goals recommended by FAO/WHO [should be] tailored to local or national diets and populations [to] reverse or reduce impact of unfavorable dietary changes occurred over the past century [and in] developing countries recently." Of course, the WTO is not about to base trade rules on health issues. Rather, with the assistance of the International Monetary Fund and the World Bank, Third World markets are being inundated with fast and processed foodstuffs, even as their trade balances are undermined by the importation of meat, dairy, sugar and refined grain. In short, the natural economies serving billions of people are being turned to dust by transnational agribusiness, which, in taking over local food industries and promoting bad diet, cause the need for vitamin and mineral supplements to increase at the very moment that the population's ability to access natural pharmacopeias is being curtailed by Codex's profit-maximization scheme. The rise of diet-related chronic disease is good business for biotech corporations such as Cargill that sell food and food ingredients while positioning themselves to market cancer cures, cardiovascular drugs, and dietary food supplements.

Regarding upper dosage limits for supplements, the FAO/WHO report observes, "Seldom is there a single 'best value' [instead] there is often a range of population averages consistent with maintenance of health … the recommended dietary/nutrition practice should modify the attributable risk of the undesirable exposure in that population." In other words, national-level regulations can best serve the needs of national populations. And responsible labeling practices protect consumers by informing them about the dangers of over-dosing.

The FAO/WHO study advises eating fruits and vegetables, shying away from red meat, saturated fat, and refined sugar, while exercising regularly, and avoiding television. It promotes the use of vitamins and minerals (including substances excluded from the EU directive's positive list) for fighting cancer, cardiovascular disease, diabetes, and the other ills that come from eating nutrient-stripped, flavor-added "food." Which brings us back to the opening sentence of the Codex Guidelines: "Most people who have access to a balanced diet can usually obtain all the nutrients they require from their normal diet."
Conclusion
Clearly, most people, even in America, do not have access to a balanced diet and the nutrients they require. Supplements are one way of alleviating the symptoms of a globalizing problem that can only be solved by an epochal transformation of the planet's political economy. It is not just irresponsible for the Codex Commission to throttle the global market in food and food supplements when 2.8 billion people are forced to live on less than two dollars a day; it is malign.

But even in the world's most over-consuming society, corporate domination of the food and drug supply is wreaking havoc. As reported in the Journal of the American Medical Association, and elsewhere, food-borne diseases contribute to approximately 76 million illnesses, 323,000 hospitalizations, and 5,200 deaths in the United States alone each year, while properly prescribed and administered prescription and over the counter drugs are estimated to cause annually 2.2 million serious adverse events, and some 106,000 deaths in the United States—while "regulators" sit by idly. The normal use of vitamins and minerals, on the other hand, is not a death sentence.
 
I don't know about other people, but starting this winter I started supplementing my diet with about 5000 IUs of Vitamin D daily to offset what I don't get because of lack of sun exposure and I haven't gotten sick once this winter. I also supplement my diet with Vitamin B complex as well as Zinc and Manganese and I feel a whole lot better, sleep better and exercise better these days.
Thanks for sharing your first hand experience. I've read about vitamin D, and have been wondering if I should give it a try. I usually get by with lots of buffered vitamin C, echinacea, propoli, milk thistle, and angelica. I actually tried ordering vitamin C from the U.S., and I can tell you that Italy has put a new system in place to discourage supplement imports from the U.S..

First, I was required to get a doctor's note for the import of vitamin C, which can be bought over the counter in Italy. Secondly, the package was stopped in customs for a medical inspection, which took ages. The combined cost of the inspection, and UPS fees were almost triple what I spent on the vitamins. I also had to do numerous faxes, e-mails, and phone calls to facilitate the whole process. Despite my having asked UPS customs, my doctor, and the vitamin company, I was given no legal basis for the medical inspection, nor the requirement for a doctor's note. It seems they have decided to interpret laws made to stop drug trafficking to stop low cost supplement imports. Pharmaceutical companies already have control of the supplement market in most of the European Union. If you have any doubt, just compare U.S. supplement prices to, say those of the U.K..
 
So it really has gotten tough to get vitamins in the EU or at least Italy. I convinced my girl friend, who's a primary school teacher, to start taking vitamins D, B, etc. and she's told me how everyone around her has gotten sick while, for the first time in years, she hasn't.

I found this articleon D in Science Daily:

The Antibiotic Vitamin

Deficiency in vitamin D may predispose people to infection

Janet Raloff

In April 2005, a virulent strain of influenza hit a maximum-security forensic psychiatric hospital for men that's midway between San Francisco and Los Angeles. John J. Cannell, a psychiatrist there, observed with increasing curiosity as one infected ward after another was quarantined to limit the outbreak. Although 10 percent of the facility's 1,200 patients ultimately developed the flu's fever and debilitating muscle aches, none did in the ward that he supervised.

a7863_1347.jpg

WINTER WOES. Cold-weather wear and the sun's angle in the winter sky limit how much ultraviolet light reaches the skin. This can add up to a deficiency in production of vitamin D, which might explain why respiratory infections are common and severe in winter.
iStockphoto

"First, the ward below mine was quarantined, then the wards on my right, left, and across the hall," Cannell recalls. However, although the 32 men on his ward at Atascadero (Calif.) State Hospital had mingled with patients from infected wards before their quarantine, none developed the illness.

Cannell's ward was the only heavily exposed ward left unaffected. Was it by mere chance, Cannell wondered, that his patients dodged the sickness?

A few months later, Cannell ran across a possible answer in the scientific literature. In the July 2005 FASEB Journal, Adrian F. Gombart of the University of California, Los Angeles (UCLA) and his colleagues reported that vitamin D boosts production in white blood cells of one of the antimicrobial compounds that defends the body against germs.

Immediately, Cannell says, the proverbial lightbulb went on in his head: Maybe the high doses of vitamin D that he had been prescribing to virtually all the men on his ward had boosted their natural arsenal of the antimicrobial, called cathelicidin, and protected them from flu. Cannell had been administering the vitamin D because his patients, like many other people in the industrial world, had shown a deficiency.

The FASEB Journal article also triggered Cannell's recollection that children with rickets, a hallmark of vitamin D deficiency, tend to experience more infections than do kids without the bone disease. He shared his flu data with some well-known vitamin D researchers, and they urged him to investigate further.

On the basis of more than 100 articles that he collected, Cannell and seven other researchers now propose that vitamin D deficiency may underlie a vulnerability to infections by the microbes that cathelicidin targets. These include bacteria, viruses, and fungi, the group notes in a report available online for the December Epidemiology and Infection.

This is only a hypothesis, "but a very credible one" that deserves testing, says immunologist Michael Zasloff of Georgetown University in Washington, D.C.

Behind the hypothesis are recent studies that link vitamin D intake to revved-up cathelicidin production. These investigations point to an infection-fighting role for vitamin D, which is produced in skin exposed to sunlight but is present in few foods.

A study published earlier this year that investigated the relationship between vitamin D and susceptibility to tuberculosis also bolsters the idea proposed by Cannell's team. Scientists have already planned a handful of clinical trials to evaluate the antimicrobial benefits of vitamin D supplementation.

Zasloff argues that if studies support the hypothesis, "we can imagine one day treating infections not by giving somebody a drug, but by giving them safe and simple substances—like a vitamin."

Innate protection

Legions of germs come into contact with our bodies every day. Each microbe seeks a host in which it can multiply. Most would-be invaders, however, don't succeed; if not barred entry outright, they're destroyed by cellular recruits called up to participate in local immune militias.

Scientists hadn't been sure what serves as the call to arms for these immune cells and what triggers the production of their antibiotic arsenal, which includes several chemical weapons.

Over the past 5 years, a spate of studies began to shed light on the rollout of one of those munitions—cathelicidin. Dermatologist and immunologist Richard L. Gallo of the University of California, San Diego, a coauthor of many of these studies, explains that cathelicidin "targets the bad guys." It kills invaders by punching holes in the external membrane of a microbe, permitting its innards to leak out.

Molecular geneticist John H. White of McGill University in Montreal and his colleagues were the first to observe that cathelicidin production is ramped up by vitamin D—or, more specifically, by the hormone 1,25-D, the vitamin's active form (SN: 10/9/04, p. 232: http://www.sciencenews.org/articles/20041009/bob8.asp). Through a cascade of events, vitamin D transforms into a compound, called a prehormone, that circulates in blood and then is converted locally, as needed, into 1,25-D.

In the nucleus of cells, 1,25-D binds to short sequences of DNA. Known as response elements, these sequences switch on the activity of adjacent genes. "We wanted to find out what genes were next to the vitamin D response elements," White recalls.

Two of these response elements proved to be neighbors of genes that make antimicrobial peptides, cathelicidin and beta-defensin 2, the researchers reported in 2004. When the researchers administered 1,25-D to a variety of cells, production of beta-defensin 2 increased "modestly," White told Science News. In contrast, he says, the gene for making cathelicidin "went boom! Its induction was very, very strong."

Almost a year later, while hunting for triggers for cathelicidin production, Gombart confirmed the McGill finding. His group had been administering various natural signaling agents to white blood cells, which the immune system sends out to vanquish germs.

In these cells, "nothing turned on the cathelicidin gene to any degree except vitamin D. And it really turned that gene on—just cranked it up," Gombart says. "I was completely surprised."

Independently, dermatologist Mona Ståhle of the Karolinska Institute in Stockholm reached a similar conclusion when she realized that both vitamin D and several antimicrobials, including cathelicidin, are produced in the skin. She says, "It just came to me—an intuitive thought—that maybe the sun, through vitamin D production, might help regulate the skin's antimicrobial response."

So, her team administered an ointment containing a drug mimic of 1,25-D to the skin of four healthy people. The salve hit "the jackpot, right away," Ståhle says. In the May 2005 Journal of Investigative Dermatology, her team reported that where the ointment had been applied, cathelicidin-gene activity skyrocketed as much as 100-fold. The team also found evidence of a localized increase in the concentration of cathelicidin.

Tackling TB and more

Those studies, though suggestive, didn't reveal whether vitamin D directly reduced infection risk in people. Together with Gallo, microbial immunologist Robert Modlin of UCLA and his colleagues moved closer to that goal: They evaluated the vitamin's role in fending off the tuberculosis (TB) germ Mycobacterium tuberculosis.

This group, working independently of Gombart's team, had been focusing on macrophages, a type of white blood cell deployed by the immune system to gobble up and destroy germs. These defense cells have features, called toll-like receptors, that identify biochemical patterns characteristic of invading microbes. If the receptors sense an invader, they can trigger cathelicidin production.

Modlin's team showed that before making that antibiotic, those cells briefly boosted their production of vitamin D receptors and of an enzyme that converts the vitamin D prehormone into 1,25-D. However, the data suggested that significant concentrations of 1,25-D would develop only in the presence of the TB bacteria. This indicated that the microbe, and perhaps other germs, must be present for the enzyme to maximize its production of 1,25-D, Modlin says.

His group then tested whether people's blood concentrations of the prehormone are high enough to drive the production of germ-killing concentrations of cathelicidin. Black people, because of the sun-filtering effect of dark pigments in their skin, are far more likely than whites to be vitamin D deficient (SN: 10/16/04, p. 248: http://www.sciencenews.org/articles/20041016/bob9.asp). Furthermore, blacks tend to be more susceptible to TB than whites and to develop a more severe illness when infected.

The team collected blood serum from white people and from blacks. When the researchers added TB bacteria, macrophages in the serum from black participants produced 63 percent less cathelicidin—and were less likely to kill the germs—than were macrophages incubated in serum from whites.

The scientists then added vitamin D to the serum from blacks until concentrations of the prehormone matched those in the serum from whites. This boosted the macrophages' cathelicidin production and rates of TB-microbe killing to those seen when such cells were incubated in serum from whites. Modlin's group reported its findings in the March 24 Science.

The new data may explain the difference between blacks and whites in TB susceptibility. Modlin says, "We showed that serum from African American individuals did not support the production of the antibiotic by immune cells, until the serum received supplemental vitamin D."

"We're now planning to do a clinical trial and treat African Americans who are deficient with vitamin D to correct their serum levels [of the prehormone] and see if this will change their antimicrobial response," Modlin says.

Gallo is also planning a new trial. His group will compare the effectiveness of supplemental vitamin D in elevating cathelicidin concentrations when administered as oral supplements or as a skin treatment.

The team expects to see the biggest benefit in skin wounds. However, Gallo predicts that even healthy skin will exhibit somewhat elevated antimicrobial concentrations, signaling an improved resistance to infection.

Sun exposure—in moderation—might also prove therapeutic, Ståhle's team suggested in the November 2005 Journal of Investigative Dermatology. The scientists showed that in eight fair-skinned people, a single dose of ultraviolet-B radiation—just enough to evoke some skin reddening the next day—activated the vitamin D receptor and the cathelicidin gene in the exposed skin.

Ståhle is now beginning a trial of people with skin infections. A drug analog of 1,25-D will be applied to see whether it speeds wound healing.

Flu too?

Many other findings also suggested to Cannell's team that flu vulnerability might be tempered by adequate vitamin D intake. The researchers have marshaled data, gleaned from 120 or so reports over the past 70 years, suggesting a link between vitamin D and resistance to infections.

For instance, the researchers point to studies showing that in winter, colds, flu, and other respiratory diseases are more common and more likely to be deadly than they are in summer. During winter, ultraviolet-light exposure tends to be low because people spend more time indoors and the atmosphere filters out more of the sun's rays, especially at mid and high latitudes.

Cannell's group cites a 1997 study showing that the rate of pneumonia in Ethiopian children with rickets, and therefore a likely vitamin D deficiency, was 13 times as high as in children without that disease. The researchers also point to five studies since the 1930s that have linked reduced risks of infectious disease to dietary supplementation with cod liver oil, a rich source of vitamin D.

Although the arguments in the paper by Cannell's group "are provocative," White says, "I find them believable."

So does Gallo. "There are many microbes out there that rarely-to-never cause disease in immunocompetent individuals. It's not because the microbes don't choose to infect us," he notes. "It's because the body's immune defense against the microbes is sufficient to control their proliferation."

It's possible, he says, that a shortfall in vitamin D might seriously compromise that defense.

Gombart's group is developing rodents in which vitamin D modulates cathelicidin.

Until such lab animals are available, vitamin D's impact—even on flu risk—"should be explored in clinical trials," Zasloff says, because the treatment poses little risk to people.

Moreover, he argues, the payoff from any positive finding "would be amazing. Imagine being able to block the spread of epidemic flu with appropriate doses of this vitamin."

Letters:

This article reminds me that in preantibiotic days, tuberculosis patients were put on a fresh-air-and-sunshine regimen. Could the vitamin D so acquired account for the cures this system sometimes produced?

Nancy Axford
Sacramento, Calif.

Researcher John J. Cannell points to TB sanitariums as anecdotal evidence that sunlight fights infections.—J. Raloff

Does the vitamin D in milk help protect against infection?

Graeme McRae
Palmdale, Calif.

Probably not, according to Michael Holick of Boston University, who has measured the vitamin's content in milk. Far better, he says, would be cod-liver oil, with "a whopping 1,360 [international units of vitamin D] per tablespoon."—J. Raloff
 
Thank you Rick for the info about Vit D.

The next was pointed out to me by a colleague.

J Clin Invest. 2007 Mar 1;117(3):803-811.

Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism.

An essential element of the innate immune response to injury is the capacity to recognize microbial invasion and stimulate production of antimicrobial peptides. We investigated how this process is controlled in the epidermis. Keratinocytes surrounding a wound increased expression of the genes coding for the microbial pattern recognition receptors CD14 and TLR2, complementing an increase in cathelicidin antimicrobial peptide expression. These genes were induced by 1,25(OH)(2) vitamin D(3) (1,25D3; its active form), suggesting a role for vitamin D(3) in this process. How 1,25D3 could participate in the injury response was explained by findings that the levels of CYP27B1, which converts 25OH vitamin D(3) (25D3) to active 1,25D3, were increased in wounds and induced in keratinocytes in response to TGF-beta(1). Blocking the vitamin D receptor, inhibiting CYP27B1, or limiting 25D3 availability prevented TGF-beta(1) from inducing cathelicidin, CD14, or TLR2 in human keratinocytes, while CYP27B1-deficient mice failed to increase CD14 expression following wounding. The functional consequence of these observations was confirmed by demonstrating that 1,25D3 enabled keratinocytes to recognize microbial components through TLR2 and respond by cathelicidin production. Thus, we demonstrate what we believe to be a previously unexpected role for vitamin D(3) in innate immunity, enabling keratinocytes to recognize and respond to microbes and to protect wounds against infection.
At the following link you can find some related articles.
www(dot)ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17290304&itool=iconpmc&query_hl=17&itool=pubmed_docsum
 
Maybe this whole Vitamin D issue is why the powers that be want everyone to stay inside out of the "harmful" sun so much.

Don
 
dhess31 said:
Maybe this whole Vitamin D issue is why the powers that be want everyone to stay inside out of the "harmful" sun so much.
Yes, and use a lot of sunscreen, too.
 
An excellent, comprehensive website about cancer, its mainstream and alternative treatments, as well as the political corruption that is behind the suppression of REAL cancer cures, can be found at www.cancertutor.com

Even if you don't have, or know anyone with, cancer, it is essential reading because it gives you ALL of the facts, so that if you are ever diagnosed with cancer, or ever know anyone diagnosed with cancer, a proper, informed CHOICE can be made.
 
Another reason why pharmaceutical companies are unable to produce curative products is that they cannot patent substances that occur naturally in our environment. It has happened before that they find a substance in nature that has healing properties and then try to manufacture a substance the looks like the natural occuring one but with a slight alteration. The alteration is of such a nature that it does not effect the therapeutic effects and since it does not occur naturally it can be patented. This allows the company to have proprietary rights to the substance under a brand name for, I think, 7-12 years before a generic can be made.

There are multiple problems with this practice. Number one is if they find a substance that works, as was mentioned earlier, they have to develop a way to make one similar to it in the lab. Sometimes this is not possible so instead of releasing valuable information regarding this naturally occuring substance they keep it to themselves since they have no way of making money off of the finding.
Secondly when they do manage to manufacture a pseudo substance that works the manufactured substance does not clear the body in the same manner as the naturally occuring one. Leading to a toxic burden and undesired side effects.

What we see happening now is that the media and 'special interests' are lobbying an attack on supplement companies in an attempt to bring about government intervention and regulation. This may lead to making it difficult to obtain supplements of any kind as they will be regulated by a doctor and be on a prescription basis. If they put allopathic doctors in charge of such things we will see an end to truly therapeutic products and there use. At least until the education in the hallowed halls of medical institutions can catch up, if they are allowed to do so in a constructive and truly educational manner.
 
notanothermonday said:
What we see happening now is that the media and 'special interests' are lobbying an attack on supplement companies in an attempt to bring about government intervention and regulation. This may lead to making it difficult to obtain supplements of any kind as they will be regulated by a doctor and be on a prescription basis. If they put allopathic doctors in charge of such things we will see an end to truly therapeutic products and there use. At least until the education in the hallowed halls of medical institutions can catch up, if they are allowed to do so in a constructive and truly educational manner.
Still not looking good, even if it is starting to get more recognized in mainstream papers:

Drug firms accused of biasing doctors' training

Published online 20 November 2007 | Nature

_http://www.healthyskepticism.org/library/ref.php?id=12753
_http://www.nature.com/news/2007/071120/full/450464a.html

The uneasy link between industry and education.

Jim Giles

Can the pharmaceutical industry be trusted to fund doctors' compulsory education without introducing bias? The issue is dividing Congress, academics and drugs companies. Now, preliminary data have emerged suggesting that industry-sponsored courses skew training material in favour of commercial interests.

Pharmaceutical firms spend over US$1 billion a year to fund more than half of the continuing medical education (CME) courses that qualified physicians are required to take in the United States. Although drug firms say that they are scrupulous about separating their CME involvement from promotional activities, some may be influencing doctors, intentionally or not, and may even be putting patients' health at risk (see 'Smokescreens'). Drug companies deny this, insisting that the independent educational firms they pay to produce CME activities always operate outside industry influence. Government standards specify that commercial promotion must be kept separate from education.

Now, two small studies have attempted the first objective measurements of bias in doctors' education. Neither is large enough to settle the issue (and neither has yet been published), but their data suggest that industry sponsorship is distorting medical education.

Psychiatrist Jatinder Takhar, head of the CME office at the University of Western Ontario in London, Canada, first became interested in industry bias after attending a CME presentation on antipsychotic drugs that she had audited and approved previously. She was surprised to find that it did not match her recollection. "The data were slanted and the presentation was more promotional and less educational," she alleges.

Takhar and her colleagues went on to develop a standardized checklist of potential problems to be used for measuring bias in CME, which they published in June (J. Takhar et al . J. Cont. Educ. Health Prof. 27, 118-123; 2007). The team then applied its checklist to 17 company-sponsored CME events. Nine of these were found to be biased and should not have been approved, Takhar says. Some focused only on the sponsors' product and ignored rival treatments. In others, information on side effects associated with the sponsors' drugs was reduced to small print.

Another study, by Daniel Carlat, a psychiatrist at Tufts University School of Medicine in Somerville, Massachusetts, looked at printed CME material — typically, medical articles followed by a written test. Carlat asked his colleagues to remove information about the sponsor from exercises sent to his office during 2005 and 2006. He then calculated the ratio of positive to negative statements made about every drug mentioned in the exercises. In 14 of the 15 exercises he looked at, the drug that received the highest ratio turned out to have been made by the firm sponsoring that exercise. He is preparing his paper for submission to the American Journal of Psychiatry .

Carlat publishes a CME newsletter that operates independently of industry funding, presenting a conflict of interest to his study. Researchers shown the findings of the two studies by Nature add that the samples Carlat looked at might not be representative of all written CME exercises. They also note that, unlike Takhar, Carlat has not validated his method for estimating bias. Drug companies also point out that firms tend to sponsor material about disorders for which they sell the best treatment, so it is right that those exercises focus on the sponsors' drugs. Yet interviews with physicians involved in the exercises that Carlat evaluated reveal that, at least in some cases, the focus is not simply the result of sponsors' drugs outperforming those of their rivals.

One exercise Carlat looked at was based on talks on bipolar disorder given at the 2005 US Psychiatric and Mental Health Congress. Anton Porsteinsson of the University of Rochester Medical Center in New York gave one of the presentations. Porsteinsson alleges that he mentioned problems with a sponsor's drug — Depakote (divalproex), manufactured by Abbott Laboratories in Illinois — in his talk, but that these were missing from the exercise. Yet he claims that positive results about the drug that were not mentioned during the talk were included. In his opinion, "the big issue is that the article is selective". Abbott denies claims that the presentation was distorted. A spokeswoman says that the firm had reviewed the material and found it to be in line with current thinking on bipolar disorder.

When asked about Carlat and Takhar's findings, Jennifer Page, communications director at the Pharmaceutical Research and Manufacturers of America in Washington DC, said only that drug companies do adhere to her organization's CME guidelines. Those standards require a firewall between pharmaceutical firms and medical-education companies. Drug companies can recommend speakers for events, for example, but CME providers select the physicians best suited for the job and are not obliged to follow a sponsor's suggestions.

But the firewall is not working, some argue. As other forms of promotion are scaled back, marketing is increasingly disguised as education, says Jerome Kassirer, a former editor of the New England Journal of Medicine , now at Tufts University in Medford, Massachusetts. "It's a reallocation of marketing money," he says.
One physician who was employed by a drug company to check the accuracy of promotional material, and who asked to remain anonymous, claims that CME material is still viewed by drug companies as part of marketing campaigns. He adds that the provider-sponsor firewall is easy to subvert, because CME providers do not need to be explicitly told to produce biased programmes. "They know that if they don't provide what the company wants then they're never going to be hired again," he claims.


The Accreditation Council for Continuing Medical Education (ACCME), based in Chicago, Illinois, which approves CME providers, acknowledges that more could be done to protect against bias. Murray Kopelow, the council's chief executive, says that next year the ACCME will launch a trial in which reviewers will check CME material and report back on problems they encounter. The council will also consider whether drug companies could be asked to pool CME funds for distribution by an independent body in a bid to reduce the influence that any one firm has over an educational exercise.

-----------------

Box: Smokescreens


Some continuing medical education (CME) programmes have been accused of putting patient care at risk. One controversy centres on whether women who are pregnant should be tested for the herpes simplex virus. About one-quarter of women carry the virus, and it can harm their babies. But the chances of a mother infecting her child are very low. The extent to which treatment can protect babies is uncertain, and herpes drugs can cause side effects such as hypertension. Organizations such as the US Preventive Services Task Force, part of the Department of Health and Human Services, therefore advise against screening for herpes in women who are pregnant.

That advice has not stopped drug giant GlaxoSmithKline from funding CME activities in which doctors advocate testing and, when necessary, treating pregnant women for herpes. If screening were introduced, the firm would potentially see a jump in sales of its herpes drug Valtrex (valacyclovir). The CME programme "flies in the face of what expert panels recommend", says Adam Urato, an obstetrician at the New England Medical Center in Boston, Massachusetts. "It's about selling Valtrex." GlaxoSmithKline denies this, saying that it recognizes the expert advice and does not promote the use of its drug in pregnant women. The firm funds events, says spokeswoman Mary Rhyne, but the organizers select the speakers and set the content. J.G.
 
There is a relevant article called 'Forbidden Cures' here:

_http://educate-yourself.org/fc/

(scroll down past contents)

U.S. laws regarding health issues are quickly adopted by the EU, it seems.
 
Back
Top Bottom